Tezepelumab
Structural basis for inhibition of TSLP-signaling by Tezepelumab (PDB 5J13) | |
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Human |
| Target | thymic stromal lymphopoietin (TSLP) |
| Clinical data | |
| Trade names | Tezspire |
| Other names | MEDI9929, AMG 157, tezepelumab-ekko |
| AHFS/Drugs.com | Monograph |
| MedlinePlus | a622010 |
| License data |
|
| Routes of administration | Subcutaneous |
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Formula | C6400H9844N1732O1992S52 |
| Molar mass | 144590.40 g·mol−1 |
Tezepelumab, sold under the brand name Tezspire, is a human monoclonal antibody used for the treatment of asthma, developed and sold by AstraZeneca . Tezepelumab blocks thymic stromal lymphopoietin (TSLP), an epithelial cytokine that has been suggested to be critical in the initiation and persistence of airway inflammation.
Tezepelumab was approved for medical use in the United States in December 2021, and in the European Union in September 2022. The US Food and Drug Administration (FDA) considered it 2021 to be a first-in-class medication.